Sifted UK: Yazen raises €19.5m to expand obesity treatment in the EU
Yazen has secured €19.5 million in Series A funding to expand its GLP-1-based obesity treatment across Europe. The company combines medication with lifestyle support for sustainable weight loss results.
Yazen secures €19.5m Series A to expand GLP-1-based obesity treatment across Europe - article in Sifted
Swedish healthtech startup Yazen, specialising in GLP-1 weight-loss and diabetes medications combined with lifestyle support, has raised €19.5 million in Series A funding. Led by Evli Growth Partners and Helsana HealthInvest, this is the largest funding round for a European startup in this field to date. Yazen, founded in 2021 by healthcare experts behind Min Doktor, reports 20,000 active users with over 200 tons of collective weight loss.
The funding will support Yazen’s European expansion, with current operations in Sweden and soft launches in the Netherlands, Norway, and Spain, as well as pilot projects in the UK and Germany. Yazen employs healthcare professionals with dual certifications, reducing expansion costs by avoiding local offices.
Yazen is profitable in Sweden, generating €18 million in annual recurring revenue and operating with a team of 150, half of whom are general practitioners. CEO Fredrik Meurling is optimistic about overcoming supply chain issues affecting GLP-1 drugs in Europe, predicting Yazen’s trajectory toward unicorn status as demand for digital obesity solutions grows.
References: Link to Sifted
More news
Yazen achieved record-breaking growth in 2025, doubling its revenue.
In 2025, Yazen's revenue surged 87% to nearly €29.4 million, with gross profits doubling to €16.5 million. Now treating over 37,000 active patients across seven countries, the company is eyeing further expansion into two more markets in 2026. Despite an EBITDA of –€5.7 million due to heavy growth investment, Yazen remains a leader in European obesity care.
